Individual Patient Compassionate Use of Mirdametinib

Clinical trial NCT05028166 · AVAILABLE

Trial details

NCT number: NCT05028166
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Status: AVAILABLE
Study type: EXPANDED_ACCESS

Neurofibromatosis Type 1-Associated Plexiform Neurofibromas Histiocytic Neoplasm Other MAP-K Pathway Driven Diseases

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.